Imagion Biosystems Appendix 4G and Corporate Governance Statement for the financial year ended 31 December 2018 is available. Download Appendix 4G.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance